Sweden's Arjo Q2 revenue beats estimates on product demand

Arjo AB (publ)

14/07/2026 06:11

Overview
Sweden healthcare equipment firm's Q2 revenue grew 4.7% organically, beating analyst expectations
Adjusted EBITDA and adjusted EBIT for Q2 both beat analyst expectations
Company expanded management team and received SEK 22 mln initial US tariff refund

Outlook
Company did not provide specific guidance for future quarters or the full year

Result Drivers
PRODUCT DEMAND - Co said high demand for its products and solutions drove organic growth in the quarter, per CEO Andréas Elgaard
MANAGEMENT TEAM EXPANSION - Co expanded management team to include five regional managers to enhance commercial focus and execution capabilities
US TARIFF REFUND - Co received initial SEK 22 mln refund related to US tariffs previously paid under IEEPA

Company press release: ID:nWkrblKwwd

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
SEK 2.76 bln
SEK 2.71 bln (5 Analysts)
Q2 Adjusted EBITDA
Beat
SEK 482 mln
SEK 470 mln (4 Analysts)
Q2 Adjusted EBIT
Beat
SEK 211 mln
SEK 196.82 mln (5 Analysts)
Q2 Adjusted Free Cash Flow
 
SEK 257 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Arjo AB (publ) is SEK30.00, about 12.5% above its July 13 closing price of SEK26.66
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)